TP53 and minimally invasive lung adenocarcinoma: Matched TP53 alterations in colorectal cancer (CRC) dominated 29.3% (n = 17), followed by pancreatic adenocarcinoma 17.2% (n = 10), and BAC 12.1% (n = 7).